Your browser doesn't support javascript.
loading
Identification and validation of ferroptosis-related lncRNA signature as a prognostic model for skin cutaneous melanoma.
Guo, Sen; Chen, Jianru; Yi, Xiuli; Lu, Zifan; Guo, Weinan.
Afiliación
  • Guo S; Department of Dermatology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
  • Chen J; Department of Dermatology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
  • Yi X; Department of Dermatology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
  • Lu Z; Department of Biopharmaceuticals, School of Pharmacy, Fourth Military Medical University, Xi'an, China.
  • Guo W; Department of Dermatology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
Front Immunol ; 13: 985051, 2022.
Article en En | MEDLINE | ID: mdl-36248853
ABSTRACT

Background:

Melanoma is a type of skin cancer, which originates from the malignant transformation of epidermal melanocytes, with extremely high lethality. Ferroptosis has been documented to be highly related to cancer pathogenesis and the effect of immunotherapy. In addition, the dysregulation of lncRNAs is greatly implicated in melanoma progression and ferroptosis regulation. However, the significance of ferroptosis-related lncRNA in melanoma treatment and the prognosis of melanoma patients remains elusive.

Methods:

Via Least Absolute Shrinkage Selection Operator (LASSO) regression analysis in the TCGA SKCM database, a cutaneous melanoma risk model was established based on differentially-expressed ferroptosis-related lncRNAs (DEfrlncRNAs). The nomogram, receiver operating characteristic (ROC) curves, and calibration plots were conducted to examine the predictive performance of this model. Sequentially, we continued to analyze the differences between the high- and low-risk groups, in terms of clinical characteristics, immune cell infiltration, immune-related functions, and chemotherapy drug sensitivity. Moreover, the expressions of DEfrlncRNAs, PD-L1, and CD8 were also examined by qRT-PCR and immunohistochemical staining in melanoma tissues to further confirm the potential clinical implication of DEfrlncRNAs in melanoma immunotherapy.

Results:

16 DEfrlncRNAs were identified, and a representative risk score for patient survival was constructed based on these 16 genes. The risk score was found to be an independent prognostic factor for the survival of melanoma patients. In addition, the low-risk group of patients had higher immune cell infiltration in the melanoma lesions, higher sensitivity to chemotherapeutic agents, and a better survival prognosis. Besides, the high expression of the identified 5 DEfrlncRNA in the low-risk group might suggest a higher possibility to benefit from immune checkpoint blockade therapy in the treatment of melanoma.

Conclusion:

The DEfrlncRNA risk prediction model related to ferroptosis genes can independently predict the prognosis of patients with melanoma and provide a basis for evaluating the response of clinical treatment in melanoma.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / ARN Largo no Codificante / Ferroptosis / Melanoma Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Humans Idioma: En Revista: Front Immunol Año: 2022 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / ARN Largo no Codificante / Ferroptosis / Melanoma Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Humans Idioma: En Revista: Front Immunol Año: 2022 Tipo del documento: Article País de afiliación: China